Annual SG&A
$71.67 M
-$7.63 M-9.62%
31 December 2023
Summary:
Allogene Therapeutics annual selling, general & administrative expenses is currently $71.67 million, with the most recent change of -$7.63 million (-9.62%) on 31 December 2023. During the last 3 years, it has risen by +$6.42 million (+9.83%). ALLO annual SG&A is now -9.62% below its all-time high of $79.31 million, reached on 31 December 2022.ALLO Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$16.33 M
+$246.00 K+1.53%
30 September 2024
Summary:
Allogene Therapeutics quarterly selling, general & administrative expenses is currently $16.33 million, with the most recent change of +$246.00 thousand (+1.53%) on 30 September 2024. Over the past year, it has dropped by -$708.00 thousand (-4.15%). ALLO quarterly SG&A is now -22.23% below its all-time high of $21.00 million, reached on 31 December 2022.ALLO Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$6.64 B
-$285.90 M-4.50%
30 September 2024
Summary:
Allogene Therapeutics TTM selling, general & administrative expenses is currently -$6.64 billion, with the most recent change of -$285.90 million (-4.50%) on 30 September 2024. Over the past year, it has dropped by -$6.72 billion (-8904.31%). ALLO TTM SG&A is now -4730.46% below its all-time high of $79.31 million, reached on 31 December 2022.ALLO TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ALLO Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -9.6% | -4.2% | -8904.3% |
| 3 y3 years | +9.8% | -14.0% | -9419.6% |
| 5 y5 years | +74.9% | +8.8% | -10000.0% |
ALLO Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -9.6% | +9.8% | -22.2% | +1.5% | -128.7% | at low |
| 5 y | 5 years | -9.6% | +74.9% | -22.2% | +8.8% | -518.5% | at low |
| alltime | all time | -9.6% | +74.9% | -22.2% | +528.9% | -4730.5% | at low |
Allogene Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $16.33 M(+1.5%) | $66.91 M(-1.0%) |
| June 2024 | - | $16.09 M(-6.8%) | $67.62 M(-3.5%) |
| Mar 2024 | - | $17.27 M(+0.2%) | $70.06 M(-2.3%) |
| Dec 2023 | $71.67 M(-9.6%) | $17.22 M(+1.1%) | $71.67 M(-5.0%) |
| Sept 2023 | - | $17.04 M(-8.0%) | $75.45 M(-2.4%) |
| June 2023 | - | $18.52 M(-1.9%) | $77.31 M(-1.3%) |
| Mar 2023 | - | $18.88 M(-10.1%) | $78.29 M(-1.3%) |
| Dec 2022 | $79.31 M(+7.0%) | $21.00 M(+11.1%) | $79.31 M(+1.3%) |
| Sept 2022 | - | $18.90 M(-3.1%) | $78.26 M(-0.1%) |
| June 2022 | - | $19.51 M(-2.0%) | $78.37 M(+0.9%) |
| Mar 2022 | - | $19.90 M(-0.3%) | $77.64 M(+4.8%) |
| Dec 2021 | $74.11 M | $19.96 M(+5.1%) | $74.11 M(+4.0%) |
| Sept 2021 | - | $19.00 M(+1.1%) | $71.28 M(+3.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2021 | - | $18.78 M(+14.8%) | $68.90 M(+4.4%) |
| Mar 2021 | - | $16.36 M(-4.5%) | $65.98 M(+1.1%) |
| Dec 2020 | $65.26 M(+13.5%) | $17.13 M(+3.1%) | $65.26 M(+3.0%) |
| Sept 2020 | - | $16.62 M(+4.8%) | $63.33 M(+2.6%) |
| June 2020 | - | $15.86 M(+1.4%) | $61.73 M(+2.8%) |
| Mar 2020 | - | $15.64 M(+2.8%) | $60.06 M(+4.5%) |
| Dec 2019 | $57.47 M(+40.2%) | $15.21 M(+1.3%) | $57.47 M(+1.2%) |
| Sept 2019 | - | $15.02 M(+5.8%) | $56.80 M(+7.0%) |
| June 2019 | - | $14.19 M(+8.6%) | $53.10 M(+3.2%) |
| Mar 2019 | - | $13.06 M(-10.2%) | $51.44 M(+25.5%) |
| Dec 2018 | $40.98 M | $14.54 M(+28.5%) | $40.98 M(+55.0%) |
| Sept 2018 | - | $11.32 M(-9.7%) | $26.44 M(+74.8%) |
| June 2018 | - | $12.53 M(+382.3%) | $15.12 M(+482.3%) |
| Mar 2018 | - | $2.60 M | $2.60 M |
FAQ
- What is Allogene Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Allogene Therapeutics?
- What is Allogene Therapeutics annual SG&A year-on-year change?
- What is Allogene Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Allogene Therapeutics?
- What is Allogene Therapeutics quarterly SG&A year-on-year change?
- What is Allogene Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Allogene Therapeutics?
- What is Allogene Therapeutics TTM SG&A year-on-year change?
What is Allogene Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of ALLO is $71.67 M
What is the all time high annual SG&A for Allogene Therapeutics?
Allogene Therapeutics all-time high annual selling, general & administrative expenses is $79.31 M
What is Allogene Therapeutics annual SG&A year-on-year change?
Over the past year, ALLO annual selling, general & administrative expenses has changed by -$7.63 M (-9.62%)
What is Allogene Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of ALLO is $16.33 M
What is the all time high quarterly SG&A for Allogene Therapeutics?
Allogene Therapeutics all-time high quarterly selling, general & administrative expenses is $21.00 M
What is Allogene Therapeutics quarterly SG&A year-on-year change?
Over the past year, ALLO quarterly selling, general & administrative expenses has changed by -$708.00 K (-4.15%)
What is Allogene Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of ALLO is -$6.64 B
What is the all time high TTM SG&A for Allogene Therapeutics?
Allogene Therapeutics all-time high TTM selling, general & administrative expenses is $79.31 M
What is Allogene Therapeutics TTM SG&A year-on-year change?
Over the past year, ALLO TTM selling, general & administrative expenses has changed by -$6.72 B (-8904.31%)